Drug facts
MoleculeRegadenoson (Lexiscan)
Generics already compete: 11 makers on the market. 11 A-rated products from 11 makers substitute at the counter.
Lexiscan was first approved by the FDA on 04/10/2008 under NDA 022161; the application holder is Astellas Pharma US Inc.
The most recent FDA recall on record is a Class II recall dated 10/30/2024.
Holder Astellas Pharma US IncApplication NDA 022161Approved 04/10/2008
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
94days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved04/10/2008
Last patent02/02/2027
2009201220152018202120242027
- Latest patent
- 02/02/2027Lexiscan Orange Book
02Competition
- Generics
- 11 generic makers Orange Book
- First generic approved
- 04/11/2022 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Regadenoson profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- Latest recall
- 10/30/2024Class II, Regadenoson, Baxter Healthcare Corporation FDA enforcement
04Product
- Application holder
- Astellas Pharma US Inc Orange Book
- Application
- NDA 022161 Orange Book
- First approved
- 04/10/2008 Orange Book
- Dosage forms
- solution
- Routes
- intravenous
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.